Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
Rana Abdelnabi, Caroline S. Foo, Suzanne J. F. Kaptein, et al.
EBioMedicine (2021) Vol. 72, pp. 103595-103595
Open Access | Times Cited: 130

Showing 1-25 of 130 citing articles:

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Christopher Butler, Richard Hobbs, Oghenekome Gbinigie, et al.
The Lancet (2022) Vol. 401, Iss. 10373, pp. 281-293
Open Access | Times Cited: 316
Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model
Rana Abdelnabi, Caroline S. Foo, Steven De Jonghe, et al.
The Journal of Infectious Diseases (2021) Vol. 224, Iss. 5, pp. 749-753
Open Access | Times Cited: 124
The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
Rana Abdelnabi, Caroline S. Foo, Dirk Jochmans, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 112
Molnupiravir: A new candidate for COVID‐19 treatment
Fariba Pourkarim, Samira Pourtaghi‐Anvarian, Haleh Rezaee
Pharmacology Research & Perspectives (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 110
Molnupiravir and Its Antiviral Activity Against COVID-19
Lili Tian, Zehan Pang, Maochen Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 102
Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice
Ju Hwan Jeong, Santosh Chokkakula, Seong Cheol Min, et al.
Antiviral Research (2022) Vol. 208, pp. 105430-105430
Open Access | Times Cited: 67
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
Two Green Micellar HPLC and Mathematically Assisted UV Spectroscopic Methods for the Simultaneous Determination of Molnupiravir and Favipiravir as a Novel Combined COVID-19 Antiviral Regimen
Yasmine Ahmed Sharaf, Sami El Deeb, Adel Ehab Ibrahim, et al.
Molecules (2022) Vol. 27, Iss. 7, pp. 2330-2330
Open Access | Times Cited: 64
Highly sensitive high‐performance thin‐layer chromatography method for the simultaneous determination of molnupiravir, favipiravir, and ritonavir in pure forms and pharmaceutical formulations
Roshdy E. Saraya, Sami El Deeb, Baher I. Salman, et al.
Journal of Separation Science (2022) Vol. 45, Iss. 14, pp. 2582-2590
Closed Access | Times Cited: 64
Pharmacological treatment of COVID-19: an opinion paper
Alberto García‐Lledó, Javier Gómez‐Pavón, Juan González del Castillo, et al.
Revista Española de Quimioterapia (2021) Vol. 35, Iss. 2, pp. 115-130
Open Access | Times Cited: 62
Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2—A narrative review
Sri Masyeni, Muhammad Iqhrammullah, Andri Frediansyah, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 7, pp. 3006-3016
Open Access | Times Cited: 62
Identification of a therapeutic interfering particle—A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance
Sonali Chaturvedi, Gustavo Vasen, Michael Pablo, et al.
Cell (2021) Vol. 184, Iss. 25, pp. 6022-6036.e18
Open Access | Times Cited: 57
Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity
Ikbel Hadj Hassine, Manel Ben M’hadheb-Gharbi, Luis Menéndez‐Arias
Viruses (2022) Vol. 14, Iss. 4, pp. 841-841
Open Access | Times Cited: 42
Computational Analysis of Molnupiravir
Artem V. Sharov, Tatyana M. Burkhanova, Tuğba Taşkın‐Tok, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1508-1508
Open Access | Times Cited: 40
Comparative evaluation of authorized drugs for treating Covid‐19 patients
Towhidul Islam, Moynul Hasan, Mohammad Saydur Rahman, et al.
Health Science Reports (2022) Vol. 5, Iss. 4
Open Access | Times Cited: 38
The Combination of Molnupiravir with Nirmatrelvir or GC376 Has a Synergic Role in the Inhibition of SARS-CoV-2 Replication In Vitro
Anna Gidari, Samuele Sabbatini, Elisabetta Schiaroli, et al.
Microorganisms (2022) Vol. 10, Iss. 7, pp. 1475-1475
Open Access | Times Cited: 38
Favipiravir for Treatment of Outpatients With Asymptomatic or Uncomplicated Coronavirus Disease 2019: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
Marisa Holubar, Aruna Subramanian, Natasha Purington, et al.
Clinical Infectious Diseases (2022) Vol. 75, Iss. 11, pp. 1883-1892
Open Access | Times Cited: 37
Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19
Renato Martins da Silva, Paula Gebe Abreu Cabral, Sávio Bastos de Souza, et al.
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 30
Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patients
Alexandra Y. Kreins, Emma Roux, Juanita Pang, et al.
Clinical Immunology (2024) Vol. 259, pp. 109901-109901
Open Access | Times Cited: 8
Broad‐spectrum prodrugs with anti‐SARS‐CoV‐2 activities: Strategies, benefits, and challenges
Zhonglei Wang, Liyan Yang
Journal of Medical Virology (2021) Vol. 94, Iss. 4, pp. 1373-1390
Closed Access | Times Cited: 43
COVID-19 lung disease shares driver AT2 cytopathic features with Idiopathic pulmonary fibrosis
Saptarshi Sinha, Vanessa Castillo, Celia R. Espinoza, et al.
EBioMedicine (2022) Vol. 82, pp. 104185-104185
Open Access | Times Cited: 31
Timing of exposure is critical in a highly sensitive model of SARS-CoV-2 transmission
Ketaki Ganti, Lucas M. Ferreri, Chung-Young Lee, et al.
PLoS Pathogens (2022) Vol. 18, Iss. 3, pp. e1010181-e1010181
Open Access | Times Cited: 27
Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens
Irfan Ullah, Fanny Escudié, Ivan Scandale, et al.
iScience (2024) Vol. 27, Iss. 3, pp. 109049-109049
Open Access | Times Cited: 6
Innovative eco-friendly stability-indicating HPLC-PDA method for simultaneous determination of the emerging antiviral drugs against COVID-19 infection molnupiravir and favipiravir; degradation kinetic studies along with LC-MS based structure elucidation
Hoda M. Marzouk, Amira S. Gouda, Mamdouh R. Rezk, et al.
Microchemical Journal (2024) Vol. 205, pp. 111197-111197
Closed Access | Times Cited: 6
New perspective of small-molecule antiviral drugs development for RNA viruses
Shasha Li, Huixia Li, Ruiya Lian, et al.
Virology (2024) Vol. 594, pp. 110042-110042
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top